This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FX005

Flexion Therapeutics, Inc.

Drug Names(s): FX-005

Description: FX005 is a intra-articular p38-MAPK inhibitor. FX005 is an anti-inflammatory drug-candidate that incorporates analgesic effects and has the potential to modify disease progression.

Deal Structure: AstraZeneca and Flexion
In June 2009, Flexion entered into an exclusive license agreement with AstraZeneca for FX005. The agreement grants Flexion an exclusive, royalty-bearing, world-wide right and license (with a right to sublicense) under AstraZenecas patent rights and certain know-how covering FX005.

Flexion paid AstraZeneca a non-refundable fee upon execution of the agreement and will owe up to an aggregate of $17 million upon the achievement of certain regulatory and development milestones for a first licensed product for OA indications or up to an aggregate of $11 million upon the achievement of certain regulatory and development milestones for a first licensed product for non-OA indications. Upon commercialization of a product that results from the technology licensed under the agreement, Flexion will owe AstraZeneca tiered royalty payments on net sales based on a percentage ranging from low to high single digits, depending on the volume of sales of the...See full deal structure in Biomedtracker

Partners: AstraZeneca PLC


FX005 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug